


# Continuous Renal Replacement Therapy Market worth \$25.37 billion by 2030 -Exclusive Report by 360iResearch

The Global Continuous Renal Replacement Therapy Market to grow from USD 13.17 billion in 2022 to USD 25.37 billion by 2030, at a CAGR of 8.53%.

PUNE, MAHARASHTRA, INDIA,
November 10, 2023 /
EINPresswire.com/ -- The "Continuous
Renal Replacement Therapy Market by
Product (CRRT Systems, Dialysates &
Replacement Fluids, Disposables),
Modality (Continuous Venovenous
Hemodiafiltration, Continuous
Venovenous Hemodialysis, Continuous
Venovenous Hemofiltration), Age
Group, Indication, End User - Global



Forecast 2023-2030" report has been added to 360iResearch.com's offering.

The Global Continuous Renal Replacement Therapy Market to grow from USD 13.17 billion in 2022 to USD 25.37 billion by 2030, at a CAGR of 8.53%.

Request a Free Sample Report @ <a href="https://www.360iresearch.com/library/intelligence/continuous-renal-replacement-">https://www.360iresearch.com/library/intelligence/continuous-renal-replacement-</a>

therapy?utm\_source=einpresswire&utm\_medium=referral&utm\_campaign=sample

Continuous renal replacement therapy (CRRT) is a specialized medical treatment utilized for continuous dialysis to allow solute and fluid homeostasis. CRRT provides continuous renal support by mimicking the natural function of the kidneys in removing waste products, excess fluids, and electrolytes from the blood while maintaining optimal acid-base balance. The CRRT is witnessing significant growth due to several factors, including the increasing prevalence of AKI incidences globally and rising technological advancements in extracorporeal dialysis and lithotripsy. In addition, significant advantages of CRRT in intermittent blood purification boost

the market expansion. However, the high cost associated with the renal replacement procedure and concerns over potential complications during therapies subsequently hampers the growth of CRRT. Moreover, ongoing innovation and research activities, including developing novel membrane materials and advanced therapy options with improved biocompatibility and widening uses of CCRT systems for pediatric patients, contribute to the future CRRT.

Indication: Growing adoption of non-renal indications in extracorporeal renal therapies Non-renal therapies involving CRRT include extracorporeal blood purification techniques primarily for non-kidney-related critical conditions such as sepsis, liver failure, and intoxications. These therapies facilitate the removal of toxins and excess fluids from the patient's body while maintaining normal physiological functions. On the other hand, the renal therapy of CRRT consists of treatments specifically designed for acute kidney injury (AKI). These therapies help maintain patients' fluid balance, electrolyte levels, and acid-base balance by providing continuous blood filtration and replacement in a controlled manner. Both indications play a vital role in CRRT, while compared to non-renal therapies, renal therapies focus more on treating kidney-related conditions, and non-renal treatments offer versatility during renal therapies, providing effective care for their targeted patient population with lower associated risks.

End User: Increasing uses of CRRT devices in hospitals to cater a patients need The increasing need for acute or chronic kidney disease treatments worldwide enhances the need for dialysis clinics. These specialized facilities provide patients with hemodialysis and peritoneal dialysis treatments. The home-based CRRT is growing rapidly due to advancements in portable dialysis devices that provide patients more convenience and flexibility in managing their treatment schedules. In addition, hospitals remain the major end-users of CRRT devices as they treat patients with acute kidney injuries and critical medical conditions requiring intensive care.

Modality: Utilization of continuous venovenous hemodiafiltration for liberal fluid management in renal therapies

In CRRT procedures, continuous venovenous hemodiafiltration (CVVHDF) combines hemodialysis and hemofiltration, providing efficient solute removal and optimal fluid balance management. Continuous venovenous hemodialysis (CVVHD) primarily functions through diffusive solute removal with dialysate flowing counter-current to the patient's blood in an extracorporeal circuit. This procedure provides stable hemodynamics and a lower risk of fluid overload during therapies. On the other hand, continuous venovenous hemofiltration (CVVH) employs convection-based solute removal and ultrafiltration techniques to optimize volume management through replacement fluids. It adequately manages fluid balance and removes large molecules, such as cytokines, beneficial for patients with significant systemic inflammation or sepsis.

Product: Growing prevalence toward acute kidney injury (AKI) boosting a need for CRRT devices for seamless treatment procedures

Bloodline sets are used for connecting a patient's blood circuit to the CRRT system, consisting of arterial and venous lines facilitating blood flow from the patient to the hemofilter and back. Dialysates and replacement fluids help remove toxins from patients' blood while maintaining

electrolyte balance during CRRT treatment. These solutions usually contain sodium, potassium, calcium ions, and glucose to meet specific requirements of patients with AKI. In addition, disposables are single-use products required for the CRRT procedure, including tubing sets, catheters, and connectors, among others. These components help prevent cross-contamination between patients and maintain a sterile environment. On the other hand, hemofilters are semi-permeable membranes that facilitate solute removal from blood via convection or diffusion mechanisms. CRRT systems are advanced medical devices that integrate all components required for continuous renal replacement therapy into one unit. They comprise pumps, monitors, sensors, and software algorithms to ensure precise fluid balance control and efficient solute removal from patients' bloodstreams.

Age Group: Differing CRRT requirements among pediatric population Adults have more medical comorbidities that require monitoring during CRRT sessions, such as hypertension or diabetes, which makes the use of CRRT among elderly patients less common. The age range for adult patients normally starts at 18, and elderly patients include those above the age of 65. Pediatric patients refer to young children weighing less than 10 Kg. Pediatric patients have unique physiological requirements that necessitate different considerations when implementing CRRT. The age range for pediatrics encompasses neonates (<28 days of life), infants (1 month – 1 year), toddlers (1-3 years), preschool-age children (3-5 years), school-age children (6-12 years), and adolescents (13-17 years). The provision of renal replacement therapy to younger populations, including neonates and infants, must ensure that only 10%-15% of their blood volume is removed by the extracorporeal circuit to prevent incidences of hypotension and anemia.

#### Regional Insights:

In the Americas, countries such as the United States and Canada hold a significant share of the CRRT market, with the major factors driving the growth, including the increasing prevalence of renal diseases and technological advancements and research & development activities by major companies. Additionally, in Europe, the presence of leading manufacturers, increased need for advanced therapies, and supportive government policies, such as European CE marking for renal therapy products, contribute to the expansion of the CRRT market. On the other hand, the Middle East and Africa region has witnessed a growth in need for CRRT solutions due to rising awareness about renal diseases and continuously developing healthcare infrastructure adopting new treatment options supported by clinical studies. In Asia-Pacific, China, Japan, and India are major contributors to the CRRT market growth due to factors including a large patient pool with kidney disorders, a growing medical tourism industry, and expanding healthcare infrastructure, coupled with an increasing focus on research initiatives enabling rapid adoption of advanced technologies in this region. As a result, manufacturers remain agile by adapting regulatory compliance measures and participating in strategic collaborations with governments and entities to form footprints in the CRRT market.

## **FPNV Positioning Matrix:**

The FPNV Positioning Matrix is essential for assessing the Continuous Renal Replacement Therapy Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

#### Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Continuous Renal Replacement Therapy Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

# **Key Company Profiles:**

The report delves into recent significant developments in the Continuous Renal Replacement Therapy Market, highlighting leading vendors and their innovative profiles. These include Anjue Medical Equipment Co., Ltd., Asahi Kasei Medical Co., Ltd., B. Braun SE, Baxter International Inc., Biomedica Medizinprodukte GmbH, Braun & Co. Limited, CytoSorbents Corporation, DIAMED Medizintechnik GmbH, Fresenius Medical Care AG & Co. KGaA, Infomed SA, Joline GmbH & Co. KG, Medites Pharma spol. s.r.o, Medtronic PLC, Miromatrix Medical Inc., Nextkidney B.V., Nikkiso Co., Ltd., Ningbo Tianyi Medical Devices Co., Ltd., Nipro Corporation, Nuwellis, Inc., Quanta Dialysis Technologies Limited, SB-KAWASUMI LABORATORIES, INC., Shionogi & Company, Limited, Sphingotec GmbH, SWS Hemodialysis Care Co. Ltd., Thermo Fisher Scientific Inc., and Toray Medical Co., Ltd. by Toray Industries, Inc..

Inquire Before Buying @ <a href="https://www.360iresearch.com/library/intelligence/continuous-renal-replacement-">https://www.360iresearch.com/library/intelligence/continuous-renal-replacement-</a>

therapy?utm\_source=einpresswire&utm\_medium=referral&utm\_campaign=inquire

## Market Segmentation & Coverage:

This research report categorizes the Continuous Renal Replacement Therapy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across CRRT Systems, Dialysates & Replacement Fluids, and Disposables. The Disposables is further studied across Bodyline sets & tubes and Hemofilters. The CRRT Systems commanded largest market share of 37.53% in 2022, followed by Disposables.

Based on Modality, market is studied across Continuous Venovenous Hemodiafiltration, Continuous Venovenous Hemodialysis, Continuous Venovenous Hemofiltration, and Slow Continuous Ultrafiltration. The Continuous Venovenous Hemodiafiltration commanded largest market share of 26.97% in 2022, followed by Continuous Venovenous Hemodialysis.

Based on Age Group, market is studied across Adults and Pediatrics. The Adults commanded largest market share of 88.77% in 2022, followed by Pediatrics.

Based on Indication, market is studied across Non-renal and Renal. The Renal commanded largest market share of 77.32% in 2022, followed by Non-renal.

Based on End User, market is studied across Dialysis Clinics, Homecare, and Hospitals. The Hospitals commanded largest market share of 62.12% in 2022, followed by Dialysis Clinics.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.49% in 2022, followed by Europe, Middle East & Africa.

#### **Key Topics Covered:**

- 1. Preface
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 6. Continuous Renal Replacement Therapy Market, by Product
- 7. Continuous Renal Replacement Therapy Market, by Modality
- 8. Continuous Renal Replacement Therapy Market, by Age Group
- 9. Continuous Renal Replacement Therapy Market, by Indication
- 10. Continuous Renal Replacement Therapy Market, by End User
- 11. Americas Continuous Renal Replacement Therapy Market
- 12. Asia-Pacific Continuous Renal Replacement Therapy Market
- 13. Europe, Middle East & Africa Continuous Renal Replacement Therapy Market
- 14. Competitive Landscape
- 15. Competitive Portfolio
- 16. Appendix

The report provides insights on the following pointers:

- 1. Market Penetration: Provides comprehensive information on the market offered by the key players
- 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
- 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
- 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
- 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

- 1. What is the market size and forecast of the Continuous Renal Replacement Therapy Market?
- 2. Which are the products/segments/applications/areas to invest in over the forecast period in the Continuous Renal Replacement Therapy Market?
- 3. What is the competitive strategic window for opportunities in the Continuous Renal Replacement Therapy Market?
- 4. What are the technology trends and regulatory frameworks in the Continuous Renal Replacement Therapy Market?
- 5. What is the market share of the leading vendors in the Continuous Renal Replacement Therapy Market?
- 6. What modes and strategic moves are considered suitable for entering the Continuous Renal Replacement Therapy Market?

Read More @ <a href="https://www.360iresearch.com/library/intelligence/continuous-renal-replacement-therapy?utm">https://www.360iresearch.com/library/intelligence/continuous-renal-replacement-therapy?utm</a> source=einpresswire&utm medium=referral&utm campaign=analyst

Mr. Ketan Rohom 360iResearch +1 530-264-8485 ketan@360iresearch.com

This press release can be viewed online at: https://www.einpresswire.com/article/667582465

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.